SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03029858

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Programmed Death-ligand 1(PD-L1) and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced Non-small Cell Lung Cancer (NSCLC) Patients

The study will investigate whether PD-L1 and other immuno-markers will be influenced by osimertinib treatment in advanced epidermal growth factor receptor (EGFR)T790M positive advanced NSCLC patients. In addition, we will explore whether PD-L1 and other immuno-markers can predict the safety and efficacy of subsequent use of immune checkpoint inhibitors at the time of PD due to osimertinib resistance.

NCT03029858 Small Cell Lung Cancer, Polygonal Type
MeSH: Lung Neoplasms Small Cell Lung Carcinoma
HPO: Neoplasm of the lung Small cell lung carcinoma

1 Interventions

Name: No interventions will be taken in this Observational study

Description: TAGRISSO(osimertinib/AZD9291)

Type: Other


Primary Outcomes

Description: Measure PD-L1 value Change by tumor cells(TC)/immune cells(IC) staining from the baseline to progressive disease(PD)

Measure: Measure PD-L1 value

Time: baseline and PD,up to 24 months

Description: Measure PD-L1 expression positive rate (%) change from the baseline to progressive disease(PD)

Measure: Measure PD-L1 expression positive rate (%)

Time: baseline and PD,up to 24 months

Time Perspective: Other

Case-Only


There is one SNP

SNPs


1 T790M

Small Cell Lung Cancer, Polygonal Type Lung Neoplasms Small Cell Lung Carcinoma Investigate whether PD-L1 and other immuno-markers will be influenced by osimertinib treatment in advanced EGFR T790M positive advanced NSCLC patients. --- T790M ---



HPO Nodes


HPO:
Neoplasm of the lung
Genes 43
WT1 KRAS SLC22A18 STK11 IRF1 AKT1 C11ORF95 PRKN PPP2R1B ERBB2 TRPV3 TSC1 POU6F2 TSC2 EWSR1 RELA KEAP1 REST DIS3L2 SFTPA2 GPC3 MBTPS2 LMNA PTEN BRAF BRCA2 EGFR RB1 TRIP13 PDGFRB TERT SFTPC PIK3CA TRIM28 DICER1 MAP3K8 HPGD SLCO2A1 H19 TP53 NOTCH3 BAP1 WRN
Small cell lung carcinoma